Agregabilnost trombocita i aktivnost antikoagulantnih proteina tokom stres ehokardiografije sa dobutaminom kod asimptomatskih bolesnika četiri meseca nakon perkutane koronarne intervencije

  • Zoran Jović Klinika za kardiologiju
  • Vesna Subota Military Medical Academy, Institute of Clinical Biochemistry, Belgrade, Serbia
  • Boris Džudović University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Zorica Mladenović University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Jelena Marić Kocijančić University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Predrag Djurić University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Marijan Spasić University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Nemanja Djenić Military Medical Academy, Clinic of Emergency Internal Medicine, Belgrade, Serbia
  • Radoslav Romanović Military Medical Academy, Clinic of Emergency Internal Medicine, Belgrade, Serbia
  • Vladimir Miloradović University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia
  • Radomir Matunović Military Medical Academy, Clinic of Emergency Internal Medicine, Belgrade, Serbia
  • Slobodan Obradović Military Medical Academy, Clinic of Emergency Internal Medicine, Belgrade, Serbia
Ključne reči: antitrombini;, ehokardiografija, stres;, perkutana koronarna inervencija;, trombociti, agregacija.

Sažetak


Uvod/Cilj. Agregabilnost trombocita i proces aktivacije hemostaze tokom ishemije miokarda u sklopu fizičkog ili mentalnog stresa mogu biti jedan od brojnih faktora koji utiču na proces tromboze stenta nakon perkutane koronarne intervencije (PKI). Cilj rada bio je da se ispita povezanost agregabilnosti trombocita i aktivnosti antikoagulantnih proteina sa miokardnom ishemijom tokom dobutamin stres ehokardiografije (DSE) kod asimptomatskih bolesnika, četiri meseca nakon PKI. Metode. Studijsku populaciju činila su 74 asimptomatska bolesnika koja su imala uspešnu PKI četiri meseca pre visokodozne DSE. Agregabilnost trombocita na epinefrin (EPI) i adenozin difosfat (ADP) određena je metodom optičke agregometrije – light transmission aggregometry (LTA) zajedno sa aktivnošću proteina C i antitrombina u plazmi pre i u piku opterećenja tokom stres testa. Bolesnici su bili podeljeni u nekoliko grupa shodno tome da li su imali poremećaje kontraktilnosti određenih segmenata miokarda u miru ili u naporu. Svi bolesnici su u vreme DSE bili na terapiji klopidogrelom i aspirinom. Rezultati. Nije bilo statistički značajne razlike u agregabilnosti trombocita na ADP (47,50 vs 50,20; p = 0,970) kao ni na EPI (59,30% vs 60,30%; p = 0,600) pre i u piku DSE. Statistički značajna razlika je utvrđena u aktivnosti antikoagulantnih proteina, antitrombina (84,85% vs 74,75%; p = 0,001) i proteina C (77,75% vs 67,60%; p < 0,001). Značajnost razlike u aktivnosti antitrombina i proteina C odnosi se na rezultat pre i u piku testa. Nije utvrđena značajna razlika u agregabilnosti trombocita i aktivnosti antikoagulantnih proteina u plazmi kod bolesnika sa ili bez indukovane ishemije u piku DSE. Bolesnici koji su imali povišen indeks pokretljivosti zida leve komore (wall motion score index) u piku DSE su imali veću agregabilnost trombocita na EPI nego bolesnici sa normalnom kontraktilnošću miokarda (68,60% vs 54,70% p = 0,017). Zaključak. Nema promena vrednosti u agregabilnosti trombocita pre i posle DSE, međutim, dolazi do smanjenja aktivnosti antikoagulantnih proteina u plazmi u piku testa. Agregabilnost trombocita na EPI značajno raste u piku DSE kod bolesnika sa segmentnom hipokontraktilnošću miokarda.

Biografija autora

Zoran Jović, Klinika za kardiologiju

 

 

Reference

REFERENCES

Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke sta-tistics--2008 update: a report from the American Heart Asso-ciation Statistics Committee and Stroke Statistics Subcommit-tee. Circulation 2008; 117(4): e25-146.

Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart As-sociation. Circulation 2010; 121(7): 948‒54.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future per-spectives. J Am Coll Cardiol 2007; 49(14): 1505‒16.

Obradovic S, Subota V, Baskot B, Dopudja M, Antonijević N, Djenić N, et al. Changes in platelets and anticoagulant protein activity during adenosine-exercise single-photon emission computed tomography stress test. Srp Arh Celok Lek 2010; 138(1 Suppl): 28‒32.

Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359(9): 938‒49.

Volpi E, Giusti L, Ciregia F, Da VY, Giannaccini G, Berti S, et al. Platelet proteome and clopidogrel response in patients with stable angina undergoing percutaneous coronary intervention. Clin Biochem 2012; 45(10‒11): 758‒65.

Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, et al. Investigating the mechanisms of hyporesponse to an-tiplatelet approaches. Clin Cardiol 2008; 31(3 Suppl 1): I21‒7.

Pavlović P, Tavcioski D, Stamenković E. Thrombocyte aggrega-tion, endothelial dysfunction and acute myocardial infarction. Vojnosanit Pregl 2009; 66(4): 323‒7.

Folsom AR, Ohira T, Yamagishi K, Cushman M. Low protein C and incidence of ischemic stroke and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. J Thromb Haemost 2009; 7(11): 1774‒8.

Bruley DF. Anticoagulant blood factor deficiencies (protein C). Adv Exp Med Biol 2007; 599: 1‒6.

Soare AM, Popa C. Deficiencies of proteins C, S and an-tithrombin and activated protein C resistance--their involve-ment in the occurrence of Arterial thromboses.J Med Life 2010; 3(4): 412‒5.

Maqbool S, Rastogi V, Seth A, Singh S, Kumar V, Mustaqueem A. Protein-C deficiency presenting as pulmonary embolism and myocardial infarction in the same patient. Thromb J 2013; 11(1): 19.

Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk fac-tors for venous and arterial thrombosis. Blood Transfus 2011; 9(2): 120‒38.

Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Poldermans D, et al. Stress echocardiography expert consen-sus statement European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr 2008; 9(4): 415‒37.

Gilstrap LG, Bhatia RS, Weiner RB, Dudzinski DM. Dobuta-mine stress echocardiography: A review and update. Res Rep Clin Cardiol 2014; 5: 69‒81.

Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on throm-botic events after drug-eluting stent implantation. Eur Heart J 2008; 29(8): 992‒1000.

Fleischmann KE, Hunink MG, Kuntz KM, Douglas PS. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. JAMA 1998; 280(10): 13‒20.

Roger VL, Pellikka PA, Oh JK, Bailey KR, Tajik AJ. Identifica-tion of multivessel coronary artery disease by exercise echo-cardiography. J Am Coll Cardiol 1994; 24(1): 109‒14.

Pamukcu B, Oflaz H, Acar RD, Umman S, Koylan N, Umman B, et al. The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin re-sistant platelet activation. J Thromb Thrombolysis 2005; 20(1): 17‒22.

Hüfner K, Koudouovoh-Tripp P, Kandler C, Hochstrasser T, Malik P, Giesinger J, et al. Differential changes in platelet reactivity in-duced by acute physical compared to persistent mental stress. Physiol Behav 2015; 151: 284‒91.

El-Sayed MS, Ali N, El-Sayed AZ. Aggregation and activation of blood platelets in exercise and training. Sports Med 2005; 35(1): 11‒22.

Objavljeno
2021/02/10
Rubrika
Originalni članak